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Summary The relationship between morphometric and clinical data was assessed in a series of 60 advanced
ovarian carcinomas. Morphometric parameters included nuclear area, nuclear perimeter, shortest and longest
nuclear axis, roundness coefficient, volume percentage ofepithelium (VPE) and mitotic index. All patients had
at least 5 years of follow-up. Univariate survival analysis showed that FIGO stage (P<0.001), VPE
(P<0.001), mean nuclear area (P<-0A001) and size of residual tumour (P<0.001) are significantly associated
with survival. When the response rate of these patients to cisplatin combination chemotherapy was evaluated,
variables with good prognostic outcome were residual tumour size (P = 0.01), mean nuclear area (P = 0.0006)
and s.d. of nuclear area (P = 0.0019). We conclude that morphometric parameters are able to support
diagnostic and therapeutic decisions.
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Malignant epithelial ovarian tumours account for approx-
imately 40% of ovarian malignancies. They are characterised
by a wide clinical spectrum ranging from the relatively
'innocent' borderline tumours to the fatal carcinomas. The
biological differences between these groups of tumours are
reflected in prognostic variables and treatment principles
(Friedlander and Dembo, 1991). The tumour stage, the his-
tological type and grade and the mass of residual tumour
after initial surgery are widely correlated with prognosis.
Recently, quantitative morphometric evaluation of cell and
tissue features have been shown to provide objective and
reproducible data in the diagnosis and prognosis of these
malignancies (Friedlander and Dembo, 1991).
Previous studies have shown that morphometric features
have prognostic value in borderline and malignant ovarian
tumours (Baak, 1991). Among them mitotic activity index
and volume percentage epithelium (VPE) are the most impor-
tant in classifying patients with borderline tumours and early
cancers (FIGO I) (Baak et al., 1981, 1985, 1987, 1992;
Haapasalo et al., 1989). In the late stages (FIGO III and IV),
it is important to identify the small number of patients with
favourable prognosis (Friedlander and Dembo, 1991; Baak et
al., 1992; Rollanson, 1992).
The aim of this study is to assess the value of morphomet-
ric features in predicting survival and response to chemo-
therapy treatment in 60 FIGO III and IV ovarian cancer
patients with a 5 year follow-up.
Materials and methods
Sixty patients with advanced (FIGO III and IV) epithelial
ovarian cancer, hospitalised and treated at the gynaecological
department of Metaxas Cancer Hospital of Piraeus between
February 1982 and April 1988, were studied. This group
comprised all patients who were admitted to our hospital
during this period and satisfied the following criteria: aged
between 44 and 76 years, previously untreated and without
evidence of renal or hepatic dysfunction. There were 36
serous, 20 mucinous and four endometrioid cases.
All patients underwent extensive staging including CT scan
of the abdomen, screening for lung and liver metastases and
laparotomy. With respect to the FIGO staging system, 47
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(78.3%) were classified as stage III and the remaining 13
(21.7%) stage IV (Table I). They were treated by hysterec-
tomy (where possible) and debulking procedure followed by
cisplatin in combination with cyclophosphamide chemo-
therapy (100 Mug m 2 cisplatin with adequate pre- and post-
hydration and 500 mgm-2 cyclophosphamide every 3 weeks
for six cycles). They were grouped as having residual disease
if the diameter of the largest residual mass was >2cm
and/or if they had 20 or more sites of disease and non-
residual disease (<2 cm). We also classified them according
to histological type and grading (Table I).
Patients were followed up for at least 5 years or until
death. Survival or not at 5 years was used as the most
objective criterion (Table I). Concerning response to chemo-
therapy, they were classified in two groups, those with com-
plete regression of the disease and those with partial, stable
or progressive disease.
Paraffin blocks from the primary tumour obtained from
the pathological files were used. Tissue was routinely fixed in
4% buffered neutral formaldehyde. Morphometric analysis
was applied on 5gtm sections stained with haematoxylin and
eosin. The fields were selected with the method described in
details by Fleege et al. (1991). They were fields without
inflammation, necrosis or calcification and those selected
were the most cellular, with the severest atypicality and
highest mitotic rate. In these selected fields, the nuclear area,
nuclear perimeter, shortest and longest nuclear axis and
nuclear roundness were estimated at a magnification of
x 787 (objective x63, numerical aperture 12.5). In each case
100 nuclei were evaluated in the representative sections and
their mean and standard deviations were calculated.
Table I FIGO stage, histological type and differentiation in relation
to 5-year survival
n % 5 year survival
FIGO stage
III 47 78.3 16 (34.0%)
IV 13 21.7 6 (46.1%)
Histological type
Serous 36 60.0 15 (41.6%)
Mucinous 20 33.3 6 (30.0%)
Endometrioid 4 6.6 1 (25.0%)
Differentiation
Well differentiated 9 15.0 5 (55.5%)
Moderately differentiated 36 60.0 13 (36.1%)
Poorly differentiated 15 25.0 4 (26.6%)Measurements were carried out on a 'digital image anal-
ysis' system comprising a computer based on an 80486 mic-
roprocessor, the commercially available program Image-Pro
Table II Differences in morphometric features between survivors
and non-survivors at 5 years
Feature n Mean Median PI Pb
Mean nuclear longest axis
Survivors 22 85.12 86.15 0.011 0.02
Non-survivors 38 92.22 93.42
Mean nuclear shortest axis
Survivors 22 77.08 75.54 0.001 0.002
Non-survivors 38 86.63 86.35
Mean nuclear perimeter
Survivors 22 272.12 277.37 0.002 0.003
Non-survivors 38 298.93 301.09
Mean nuclear area
Survivors 22 5058.34 5232.42 0.000 0.002
Non-survivors 38 6216.21 6206.29
Mean roundness
Survivors 22 0.8926 0.8891 0.324 0.180
Non-survivors 38 0.8991 0.9034
Mean VPE
Survivors 22 24.50 22.99 0.003 0.007
Non-survivors 38 35.62 35.32
Mitotic index
Survivors 22 18.28 14.15 0.021 0.003
Non-survivors 38 29.86 26.99
at-test; bWilcoxon rank-sum test. None of the morphometric
standard deviations had significant differences.
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II processing system (version 2.0), a microscope and tube
colour camera which was installed on top of the microscope
and generated the image previewed on a high-resolution
monitor. The cells of interest were identified on the screen
and the contours of their nuclear profiles were traced
manually. Inside the tracings, the nuclear area, nuclear
perimeter, shortest and longest nuclear axis and roundness
coefficient were determined.
The assessment of epithelial and stromal percentages was
-carried out with a point counting technique using a 63-square
grid in 20 continuous fields at x 500 magnification. In these
fields, the number of mitotic figures, corrected according to
the volume fraction (%) of the neoplastic epithelium, was
also estimated.
Statistical analysis
Differences in terms of the morphometric measurements
between tumours from survivors and non-survivors were
statistically tested using the t-test and the Wilcoxon rank-sum
statistic. Results are presented in Table II. The association
between survival and the clinical characteristics of FIGO
staging, mass of residual disease, grading and morphometric
features was tested by the usual chi-square method or by
fitting the simple linear logistic model to the corresponding
contingency tables (Cox, 1970). For this analysis the quan-
titative morphometric features (i.e. measured on continuous
scales) were categorised in three clases of approximately
equal size. Results are shown in Table III.
To find the characteristics with the highest association with
survival in a multivariate context two approaches were fol-
lowed: (a) logistic regression (Cox, 1970; Vlachonikolis and
Marriott, 1982) and (b) discriminant analysis (Morrison,
Table III Single clinical and morphometric features and their independent prognostic value;
prognostic value are shown
only features with significant independent
Median
survival time Hazard
Feature n Alive (%) P (months) Mantel-Cox P ratio
FIGO stage
III 47 22 (46.8) <0.001 47 17.972 <0.001
IV 13 0 (0.0) 19 3.988
Residual disease
<2cm 32 17 (53.1) 0.004 Not reached 10.731 <0.001
>2cm 28 5 (17.9) 24.5 2.869
Response to chemotherapy
CR 33 18 (54.5) 0.001 Not reached 16.295 <0.001
PD 27 4 (14.8) 23 3.654
Mean nuclear longest axis
- 83.2 20 8 (40.0) 0.023 34 6.302 0.043
83.2- 94.7 20 11 (55.0) Not reached 0.600
94.7+ 20 3 (15.0) 29.5 1.640
Mean nuclear shortest axis
-77.8 20 12 (60.0) 0.027 Not reached 5.949 0.051
77.8 - 87.8 21 6 (28.6) 36 2.180
87.8+ 19 4 (18.2) 28 2.798
Mean nuclear perimeter
- 274.6 20 10 (50.0) 0.035 53 6.812 0.033 274.6 - 303.7 20 9 (45.0) 48 0.974 303.7+ 20 3 (15.0) 27.5 2.278
Mean nuclear area
-5129.8 20 11 (55.0) 0.005 Not reached 13.821 <0.001
5129.8-6393.9 20 9 (45.0) 50.5 1.219 6393.9+ 20 12 (10.0) 24.5 3.624
Mean VPE
-22.5 20 11 (55.0) <0.001 Not reached 15.065 <0.001 22.5-36.0 21 10 (47.6) 47 1.247 36.0+ 19 1 (5.3) 21 3.752
Mitotic index
- 14.0 20 11(55.0) 0.023 Not reached 8.344 0.015 14.0-30.2 20 8 (40.0) 46.5 1.424 30.2+ 20 3 (15.0) 26 2.965
CR, complete regression; PR, progressive disease.Morphomtry in ovarian carcinomas
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1976; Vlachonikolis and Marriott, 1982). Both approaches
were used stepwise.
Actual survival times were analysed as follows. (a) Survival
curves (Kaplan and Meier, 1958) were analysed for each
feature or characteristic separately using the Mantel-Cox
statistic, better known as the log-rank test statistic (Kalb-
fleisch and Prentice, 1980). The categorised transformations
of the morphometric features were used also for this analysis.
Kaplan-Meier curves are shown in Figures 1-8, while the
Mantel-Cox statistics are shown in Table III. (b) Mul-
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tivariate survival analysis using Cox's proportional hazards
model. In this analysis post-operative periods of survived
patients to last-seen times are treated as censored observa-
tions and morphometric or clinical variables are used as
regressors (Cox, 1972; Kalbfleisch et al., 1980).
Similar statistical analyses were carried out with respect to
response to chemotherapy. The computations for the statis-
tical analyses were carried out using software packages
EGRET (1993) and SPSS (1992).
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Figure 1 Kaplan-Meier survival curve of our patients.
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Figure 4 Kaplan-Meier survival curves according to mean
shortest nuclear axis.
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Figure 2 Kaplan-Meier survival curves of patients with size of
residual disease <2 cm (n = 32) vs patients in which this feature
is > 2 cm (n = 28).
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Figure 5 Kaplan-Meier survival curves according to mean
nuclear area.
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Figure 3 Kaplan-Meier survival curves according to mean
longest nuclear axis.
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Figure 6 Survival curves of patients with tumours categorised
according to volume percentage epithelium.
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Figure 8 Survival curves according to the strongest combination
of prognostic features [mean nuclear area, mean volume percen-
tage epithelium (VPE), s.d. of VPE, FIGO stage and mean
nuclear perimeter]: optimum prognostic score (OPS) <0.00
(n = 22), OPS >0.00 (n = 32).
Results
Univariate analysis
Table II shows the morphometric features that were sig-
nificantly different between survivors and non-survivors.
None of the standard deviations of the morphometric
measurements were significantly different. In contrast, all
means, except for roundness were significantly different.
Similarly, the association between survival and all mor-
phometric features, with the exception of roundness, is
significant (Table III). Note that in this analysis the associa-
tion is assessed by tests based on the proportions of survivors
in the three defined categories for each feature. In the same
context, the clinical characteristics FIGO stage, mass of
residual disease and response to chemotherapy are also
significantly associated with survival; histological grading is
not.
The analysis of survival times shows similar results: all the
morphological mean features, except roundness, have signifi-
cant association with survival (Table III). Note that for each
feature, mean values greater than the 66.7 percentile of their
distribution are associated with worst prognosis; the hazard
ratios compared with values below the 33.3 percentile, range
from 1.64 for mean nuclear longest axis to 3.752 for VPE. In
particular strong associations are seen with mean nuclear
perimeter, mean nuclear area, VPE and mitotic index.
Very strong associations are also seen for FIGO stage,
response to chemotherapy and mass of residual disease.
FIGO stage IV appears to have a hazard ratio compared
Morphomntry in ovariancarcinomas
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with stage III of 3.988; in fact none of FIGO stage IV
patients survived the 5 year post-operative period and the
median survival period was only 19 months. Similarly, pro-
gressive disease is, as expected, a bad prognostic characteris-
tic having a hazard ratio compared with complete remission
of 3.654; 4 (14.8%) of the 27 patients with progressive
disease survived the 5 year post-operative period (compared
with 54.5% for patients with complete remission) and their
median survival period was 23 months. The size of residual
disease is also a bad prognostic factor, having a hazard ratio,
compared with non-residual disease, of 2.869, survival
percentage 17.9 (compared with 53.1% for non-residual
disease) and median survival period 24.5 months.
60 Multivariate analysis
Survival vs non-survival Discriminant analysis and logistic
itotic regression produced the same best combination of prognostic features: mean nuclear area, mean VPE, s.d. of VPE, FIGO
stage and mean nuclear perimeter. The resulting linear func-
tion (discriminant or regression respectively) or in this case
the optimum prognostic score (OPS) was as follows:
OPS = - 16.999 + (1.361 x mean VPE) + (19.964 x s.d. of
VPE) + (0.026 x mean nuclear area) + (18.897 x FIGO
(coded as 0 if FIGO is III and 1 if FIGO is IV))
(- 0.736 x mean nuclear perimeter)
On the basis of this score, one can classify an observation in
the survivors group if OPS <0 and in the non-survivors if
OPS >0. With our sample reclassification results were as
shown in Table IV. The overall proportion of correct re-
classification of observations was 90.0%.
The Kaplan-Meier estimates of survival curves for the
two groups (OPS <0.0 and OPS >0.0) are shown in Figure
*J 8. Their Mantel-Cox statistic was highly significant (P<
60 0.00001); the median for the group with bad prognosis (OPS
>0.0) was 24 months.
Survival analysis Cox's proportional hazards model fitted
stepwise pointed out the following best combination of prog-
nostic features: FIGO stage, mitotic index, mean VPE, s.d. of
longest nuclear axis, s.d. of VPE and s.d. of nuclear area.
The regression coefficients, standard errors, P-values and
corresponding hazard ratios are shown in Table V. Concern-
ing response to chemotherapy, the morphometric features
that were significantly different between responders and non-
responders are shown in Tables VI and VII.
Multivariate analysis (discriminant analysis and logistic
regression) of our data revealed the following best combina-
tion of prognostic features: mean nuclear area, mean nuclear
longest axis and mean nuclear shortest axis. The resulting
optimum prognostic score is as follows:
OPS = 292.9 + (0.076 x mean nuclear area)
-(4.722 x mean nuclear longest axis)
-(3.789 x mean nuclear shortest axis)
when the patients with positive value of OPS are expected to
benefit from a cisplatin combination chemotherapy in con-
trast to those with negative OPS, who will not.
Discussion
The 5 year survival rate for ovarian carcinomas depends on
the stage of the disease: 70% for stage I, 25% for stage II,
12% for stage III, 0% for stage IV (Friedlander et al., 1991).
Adjuvant chemotherapy is therefore indicated especially for
Table IV
Optiunwn prognostic score
Actual group <0.0 >0.0
Survivors (n = 22) 22 (100.0%) 0 (0.0%)
Non-survivors (n = 38) 6 (15.8%) 32 (84.2%)
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Table V
Variable Coefficient s.e. P Hazard ratio
FIGO stage (0 for III and 1 for IV) 2.110 0.414 <0.001 8.247
Mitotic index 0.022 0.008 0.008 1.022
Mean VPE 0.077 0.017 <0.001 1.080
s.d. of nuclear longest axis - 16.690 5.280 0.002 0.057
s.d. of VPE 0.897 0.333 0.007 2.452
s.d. of nuclear area 4.560 2.190 0.037 95.570
Table VI Differences in morphometric features between responders
and non-responders to chemotherapy
Feature n Mean Median pa pI
Mean nuclear longest axis
Responders 33 88.43 87.15 0.0341 0.249
Non-responders 27 91.07 93.28
Mean nuclear shortest axis
Responders 33 80.44 78.82 0.034 0.012
Non-responders 27 86.40 87.30
Mean nuclear perimeter
Responders 33 281.53 278.43 0.049 0.028
Non-responders 27 298.36 303.29
Mean nuclear area
Responders 33 5325.46 5349.56 0.001 0.002
Non-responders 27 6361.45 6453.48
Mean roundness
Responders 33 0.9010 0.907 0.136 0.141
Non-responders 27 0.8916 0.894
Mean VPE
Responders 33 32.708 30.096 0.489 0.323
Non-responders 27 30.120 23.939
Mitotic index
Responders 33 22.234 18.500 0.128 0.143
Non-responders 27 29.738 25.810
at-test; bWilcoxon's rank-sum test.
advanced epithelial ovarian cancer in addition to surgery.
Recent studies suggest that cisplatin treatment improves pro-
gnosis in approximately 30% of FIGO III and IV epithelial
ovarian cancer patients (Perez et al., 1993). However, the
outcome of treatment is not only determined by the treat-
ment itself but also by other parameters such as clinical and
morphometric observations. It is important therefore to
recognise these factors in order to identify patients at high
risk who may require aggressive treatment in order to im-
prove their survival.
Morphometry of ovarian carcinomas was studied mainly
by two groups of investigators (Baak et al., 1981, 1985,
1986a, 1986b, 1988; Haapasalo et al., 1989, 1991). In 1988
Baak et al. evaluated in 73 ovarian cancers the prognostic
significance of morphometric features and DNA content in
comparison with histological type, grade of differentiation
and a number of clinical characteristics. They concluded that
'nuclear size is an important predictor of the sensitivity of
tumour cells to cisplatin treatment' although 'it is not quite
clear which underlying cell-biological mechanism it reflects'.
In 1989 Haapsalo et al. estimated the morphometric
parameters in 105 ovarian carcinomas. Morphometric para-
meters included mitotic activity index, volume corrected
mitotic index (M/V), volume fraction of neoplastic epithe-
lium, nuclear area, nuclear perimeter, shortest and longest
nuclear axis and form factor of nucleus. Their results
indicated that clinical stage was the best predictor of prog-
nosis followed by the M/V index. The latter was the best
prognostic factor in all the tumour subgroups studied. Regar-
ding VPE their results were different from the earlier paper
of Baak et al. (1986). They indicate as a possible reason that
in Baak's material about one-third of the carcinomas were
mucinous whereas in their material only four of the cases
were mucinous carcinomas.
In our study FIGO III and IV epithelial ovarian cancer
Table VII Single clinical and morphometric features and their
independent prognostic value concerning response to chemotherapy;
only features with significant independent prognostic value are
shown
Feature n Responded (%) P
Residual disease
<2cm 32 23 (71.9%) 0.01
>2cm 28 10 (35.7%)
Mean nuclear area
-5129.8 20 15 (75.0%) 0.0006
5129.8 - 6393.9 20 14 (70.0%)
6393.9+ 20 4 (20.0%)
s.d. of nuclear area
- 1.241 20 17 (85.0%) 0.0019
1.241 - 1.338 20 10 (50.0%)
1.338+ 20 6 (30.0%)
uniformly treated patients have been included and our results
fulfil the demand of an accurate prognostic test based on
clinical and reproducible quantitative pathological features.
Our material can readily be compared with the incidence of
the histological tumour types mentioned in the literature
(DiSaia et al., 1993).
According to our results patients with low values of VPE
or mitotic index seem to have a good prognosis concerning
survival or not at 5 years (Figures 6 and 7). These findings
are in accordance with those reported in the literature (Baak
et al., 1988; Haapasalo et al., 1989). Regarding treatment
with cisplatin, these features were found not quite significant
when used for the identification of patients treated with
cisplatin. Many of these patients survived even ifthey did not
respond to the regimen used perhaps because of different cell
biological mechanisms.
Another factor of great importance is the size of the
residual tumour (Figure 2). The prognosis, as is generally
accepted, was found to be favourable if the diameter of the
largest residual mass did not exceed 2 cm and/or if there were
fewer than 20 sites of disease, regardless of the bulkiness of
the disease.
Our results also indicate that nuclear size (Figures 3-5) is
an important predictor of the response of tumour to cisplatin
chemotherapy. In this aspect the results are in agreement
with those of Baak et al. (1988), although the regimen and
dosage of treatment of our patients is different. Many
authors have compared the two regimens (cisplatin, cyclo-
phosphamide and doxorubicin used by Baak's group and
cisplatin, cyclophosphamide). Some of them were unable to
demonstrate any difference in overall response rate, in rate of
pathological response and in survival (Edmonson et al., 1985;
Neijt et al., 1987; Omura et al., 1989). Others reported higher
rate of complete response or improved survival using cis-
platin, cyclophosphamide and doxorubicin (Jakobsen et al.,
1985; Bruzzone et al., 1990). It is difficult to compare the
results of these studies because of the different dose inten-
sities used. It is clear that the combination of cisplatin with
cylcophosphamide may produce as high a response rate as
combinations with other drugs (doxorubicin, hexamethyl-
melamine) without their potential cardiac or neurological
side-effects.
It appears therefore that nuclear dimension is a significant
predictor regardless of the dosage or the regimen used, pro-
vided that cisplatin is included.Morphomety in ovariancarcinomas Id
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